ABVC | ABVC BioPharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6750 - 0.6918
52 Week Range	0.6000 - 3.35
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	24,704
Average Volume	84,816
Shares Outstanding	12,421,800
Market Cap	8,384,715
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-11-10

Valuation
Profitability
Growth
Health
P/E Ratio	-0.41
Forward P/E Ratio	N/A
EPS	-1.66
1YR Price Target	20.20
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	16
Country	USA
Website	ABVC

ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential.

ABVC's peers: ACST, ALRN, BCDA, CRDL, INDP, KTTA, BTTX, FBRX, EVLO, APTX, MGTA, ARDS, AKTX, ADTX, RNXT, ANEB, SABS, MNPR, ELDN, NTRB, QNRX, LGVN, VRAX, NNVC

*Chart delayed

Analyzing fundamentals for ABVC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see ABVC Fundamentals page.

Watching at ABVC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ABVC Technicals page.